OVID (Ovid Therapeutics) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OVID Ovid Therapeutics Inc OVID
48 GF Score
Price $2.50
GF Value $7.77
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Ovid Therapeutics Short-term investments?

Short-term investments only applies to insurance companies.

OVID
48GF Score
Ovid Therapeutics Inc OVID
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ovid Therapeutics (OVID) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued. The current stock price of $2.50 is trading 67.8% below its estimated GF Value™ of $7.77. GuruFocus considers Ovid Therapeutics to be Possible Value Trap.

Key valuation signals for OVID:

  • Short-term investments:
  • GF Value™: $7.77 vs. price of $2.50 (67.8% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ovid Therapeutics Business Description

Other Exchanges 1OT:Germany
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score

Get the complete analysis for OVID

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.50
Price
$7.77
GF Value